Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide in Adults With Overweight or Obesity
NCT07770841Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 10
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Novo Nordisk. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07770841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770841.